Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366428 | 0.89 | EPHX2 (0.58) | EPHX2FAAHCNR1HDAC1HDAC6 | |
| SCHEMBL7370758 | 0.88 | EPHX2 (0.55) | EPHX2FAAHCNR1 | |
| SCHEMBL28136625 | 0.85 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL30541869 | 0.85 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL7371165 | 0.85 | CNR1 (0.62) | EPHX2CNR1ALDH1A1HDAC1HDAC6 | |
| SCHEMBL28007018 | 0.85 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL30541868 | 0.85 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL17397649 | 0.84 | EPHX2 (0.79) | EPHX2FAAHCNR1ALDH1A1HTT | |
| SCHEMBL7372287 | 0.83 | MEN1 (0.54) | EPHX2FAAHPOLBHDAC1HDAC6 | |
| SCHEMBL934606 | 0.82 | EPHX2 (0.90) | EPHX2FAAHCNR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| US-20020103192-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-08-01 | — | — | US | disclosed |
| WO-2002046129-A2 | INHIBITORS OF HISTONE DEACETYLASE | ABBOTT LABORATORIES (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103192-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC4 | EPHX2 3092/4885FAAH 1179/4885CNR1 4370/4885 |
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | EPHX2 3982/4885FAAH 2579/4885CNR1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.